Analysed SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ) News Sources
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
27-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
28-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
29-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
01-06-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
03-06-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week
05-06-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
09-06-2026
yahoo.com
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
11-06-2026
yahoo.com
What is the current price of SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ)?
The current price of SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ) is $6.7.
SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ) absolute price change since previous trading day?
The absolute price change of SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ) since the previous trading day is $0.02.
SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ) percentage price change since previous trading day?
The percentage price change of SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ) since the previous trading day is 0.2994%.
What is the most recent average sentiment score for SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ)?
The most recent average sentiment score for SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ) is 60 out of 100.
What is the most recent average sentiment for SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ)?
The most recent sentiment for SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ) is .
SEC-8K** Filing Available For SILENCE THERAPEUTICS PLC-ADR (SLN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.